G2B and SNBL are jointly developing G2B011 for treating anaphylaxis. Sosei has recognized the potential of G2B011 to fulfill unmet clinical needs and has committed to finance the initial product expenses. In conjunction with this agreement, SNBL has granted G2B a licensing option for its nasal platform technologies. In return for providing initial project financing, Sosei will receive a portion of future G2B revenue, as well as the first negotiation right for financing the full development of the product and the right to negotiate for the licensing of worldwide development and commercialization rights for this project.
Anaphylaxis is a systemic and life-threatening allergic reaction to food allergies, insect stings, and other triggers. It is characterized by anaphylactic shock associated with a swelling of the lips, constriction of the throat, decrease in blood pressure and potential loss of consciousness. The prevalence of food allergies is estimated at 3-4% in the US and 1-2 % in
Epinephrine is considered the gold standard treatment for anaphylaxis. The only marketed products of epinephrine are injections and are mostly auto-injectors; however, only a small fraction of diagnosed at-risk anaphylaxis patients carry an auto-injector, which is in part due to needle phobia and lack of training in their use. Nevertheless, sales of auto-injectors have been increasing steadily over the last few years with EpiPen®, the leading auto-injector product, is on track to become a billion dollar product in 2014 according to its distributor Mylan Inc.
In 2013, G2B and SNBL conducted a successful proof of concept study which showed that nasally administered G2B011 demonstrates rapid and high absorption comparable to EpiPen®, and has the potential to become a novel anaphylaxis treatment.
EpiPen® is a registered trademark of Mylan Inc. Fit-lizerTM and µcoTM are trademarks of
About G2B Pharma
Sosei is an international biopharmaceutical company anchored in
For more than 55 years, SNBL (Shin Nippon Biomedical Laboratories, Ltd) has been a leader in helping biopharmaceutical companies generate high quality data with the exceptional precision needed to rapidly advance new medical therapies and innovations that improve patients' lives, SNBL has facilities in
CONTACT: For further information contact:
G2B Pharma Inc.Executive Chairman, Michael Doodson TEL: +1 (415) 320-4391 Email: firstname.lastname@example.org CEO, Nigel Fleming(Email: email@example.com) Sosei Group Corporation Milica Stojkovic, Investor Relations ( Tokyo) +81-(0)3-5210-3399, firstname.lastname@example.org Kathryn Lydon, PA to CEO & Corporate Communication ( London) +44-(0)20-7691-0983, email@example.com Shin Nippon Biomedical Laboratories, Ltd. Tokyo Stock Exchange, First Section: Code # 2395 CFO and Executive Vice President, Toshihiko Seki(TEL: +81 (0)3 5565 5001)